Long‐Term Outcome of Low‐ and High‐Dose Radioiodine for Thyroid Remnant Ablation
Clinical Endocrinology · 2024
DOI: 10.1111/cen.15134 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Endocrinology, 2024. Verfasst von Shiqi Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Neoplasms, Thyroidectomy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: This work was supported by the National Natural Science Fund of China (Grant 81974269) and the Biomedical Engineering Cross Fund of Shanghai Jiao Tong Universi….
Abstract (Originalsprache)
Objective
We conducted a prospective randomized clinical trial to compare the efficacy of low‐ and high‐dose radioiodine for remnant ablation in patients with low‐risk differentiated thyroid cancer (DTC) in China. The first‐stage results showed equivalence was observed between the two groups. Here, we report recurrence and survival at 3–5 and 6–10 years and biochemical parameters. Design, Patients and Methods Between January 2013 and December 2014, adult patients with DTC were enroled. Patients had undergone total or near‐total thyroidectomy, with or without cervical lymph node dissection, with tumour stages T1–T3 with or without lymph node metastasis, but without distant metastasis. Patients were randomly assigned to the low‐dose (1850 MBq) or high‐dose (3700 MBq) radioiodine group. They were then followed up for 3–5 and 6–10 years. Data on biochemical abnormalities, recurrence and survival were analysed using Kolmogorov–Smirnov and χ 2 tests.
Results
The data of 228 patients (mean age = 42 years; 70.6% women) were analysed, with 117 patients in the low‐dose group and 111 in the high‐dose group. There were no significant differences in biochemical abnormalities, recurrence, or survival rates at the 6–10‐year follow‐up (all p > .05). Nine patients experienced recurrence in the low‐dose group (8.7%), while eight patients experienced recurrence in the high‐dose group (8.2%). The survival rates were 100% and 98.2% in the low‐ and high‐dose groups, respectively.
Conclusions
The long‐term effectiveness and safety of low‐dose (1850 MBq) radioiodine are the same as those of high‐dose (3700 MBq) radioiodine for thyroid remnant ablation in Chinese patients with low‐risk DTC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
- Department of Nuclear Medicine, Shanghai Fourth Peoples' Hospital Affiliated to Tongji University, Shanghai, China.
Förderung
- This work was supported by the National Natural Science Fund of China (Grant 81974269) and the Biomedical Engineering Cross Fund of Shanghai Jiao Tong Universi…
Zitieren
APA
Liu, S., Wu, S., Ma, C., Wang, S., Chen, S., Wang, H., & Feng, F. (2024). Long‐Term Outcome of Low‐ and High‐Dose Radioiodine for Thyroid Remnant Ablation. Clinical Endocrinology. https://doi.org/10.1111/cen.15134
Vancouver
Liu S, Wu S, Ma C, Wang S, Chen S, Wang H, et al. Long‐Term Outcome of Low‐ and High‐Dose Radioiodine for Thyroid Remnant Ablation. Clinical Endocrinology. 2024. doi:10.1111/cen.15134
BibTeX
@article{Liu2024,
author = {Liu, Shiqi and Wu, Shuqi and Ma, Chao and Wang, Shaoyan and Chen, Suyun and Wang, Hui and Feng, Fang},
title = {Long‐Term Outcome of Low‐ and High‐Dose Radioiodine for Thyroid Remnant Ablation},
journal = {Clinical Endocrinology},
year = {2024},
doi = {10.1111/cen.15134}
}
EUVIMED